Immunotherapy for the Treatment of Urothelial Carcinoma

Journal of Urology

Volumn 197, Issue 1, 2017, Pages 14-22

  Donin, Nicholas M ^a   Lenis, Andrew T ^a   Holden, Stuart ^a   Drakaki, Alexandra ^a   Pantuck, Allan ^a   Belldegrun, Arie ^a   Chamie, Karim ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCG vaccine; cancer vaccines; cell cycle checkpoints; immunotherapy; urologic neoplasms

Indexed keywords

BCG VACCINE; CYTOKINE; IMMUNOMODULATING AGENT; ONCOLYTIC VIRUS; VALRUBICIN; CANCER VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL CYCLE CHECKPOINT; COCHRANE LIBRARY; GENE THERAPY; GOLD STANDARD; HUMAN; IMMUNOBIOLOGY; MEDLINE; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; IMMUNOTHERAPY; PROCEDURES; URINARY TRACT TUMOR;

BCG VACCINE; CANCER VACCINES; CYTOKINES; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; ONCOLYTIC VIROTHERAPY; UROLOGIC NEOPLASMS;

EID: 85003454031     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.02.3005     Document Type: Review

References (44)

1. 1 Coley, W.B., The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res, 262, 1991, 3.
2. 2 Morales, A., Eidinger, D., Bruce, A.W., Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 116, 1976, 180.
3. 3 Lawrence, M.S., Stojanov, P., Polak, P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499, 2013, 214.
4. 4 Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature, 480, 2011, 480.
5. 5 Curiel, T.J., Coukos, G., Zou, L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, 2004, 942.
6. 6 Calmette, A., Guérin, C., Boquet, A., et al. La Vaccination Préventive contre la Tuberculose par le “BCG”. 1927, Masson et Cie, Paris.
7. 7 Old, L.J., Clarke, D.A., Benacerraf, B., Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature, 184(suppl.), 1959, 291.
8. 8 deKernion, J.B., Golub, S.H., Gupta, R.K., et al. Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer, 36, 1975, 1662.
9. 9 Lamm, D.L., Thor, D.E., Harris, S.C., et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol, 124, 1980, 38.
10. 10 Redelman-Sidi, G., Glickman, M.S., Bochner, B.H., The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol, 11, 2014, 153.
11. 11 Shelley, M.D., Court, J.B., Kynaston, H., et al. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev, 4, 2000, CD001986.
12. 12 Sylvester, R.J., van der Meijden, A.P., Witjes, J.A., et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol, 174, 2005, 86.
13. 13 Lamm, D.L., Blumenstein, B.A., Crissman, J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol, 163, 2000, 1124.
14. 14 Oddens, J., Brausi, M., Sylvester, R., et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol, 63, 2013, 462.
15. 15 Morales, A., Herr, H., Steinberg, G., et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol, 193, 2015, 1135.
16. 16 Glashan, R.W., A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol, 144, 1990, 658.
17. 17 Malmström, P.U., A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int, 89, 2002, 681.
18. 18 Jimenez-Cruz, J.F., Vera-Donoso, C.D., Leiva, O., et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology, 50, 1997, 529.
19. 19 Nepple, K.G., Lightfoot, A.J., Rosevear, H.M., et al. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol, 184, 2010, 1915.
20. 20 O'Donnell, M.A., Krohn, J., DeWolf, W.C., Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol, 166, 2001, 1300.
21. 21 Lam, J.S., Benson, M.C., O'Donnell, M.A., et al. Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol, 21, 2003, 354.
22. 22 Joudi, F.N., Smith, B.J., O'Donnell, M.A., Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol, 24, 2006, 344.
23. 23 Dinney, C.P., Fisher, M.B., Navai, N., et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol, 190, 2013, 850.
24. 24 Mitra, A.P., Birkhahn, M., Cote, R.J., p53 and retinoblastoma pathways in bladder cancer. World J Urol, 25, 2007, 563.
25. 25 Burke, J.M., Lamm, D.L., Meng, M.V., et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol, 188, 2012, 2391.
26. 26 Petrulio, C.A., Kaufman, H.L., Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines, 5, 2006, 9.
27. 27 Sharma, P., Shen, Y., Wen, S., et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res, 12, 2006, 5442.
28. 28 Nishiyama, T., Tachibana, M., Horiguchi, Y., et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res, 7, 2001, 23.
29. 29 Sharma, P., Bajorin, D.F., Jungbluth, A.A., et al. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother, 31, 2008, 849.
30. 30 Zhao, J., Xu, W., Zhang, Z., et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol, 47, 2015, 87.
31. 31 Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515, 2014, 558.
32. 32 Petrylak, D.P., Powles, T., Bellmunt, J., et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol, 33(suppl.), 2015, 4501.
33. 33 Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 2010, 711.
34. 34 Carthon, B.C., Wolchok, J.D., Yuan, J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res, 16, 2010, 2861.
35. 35 Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8, 2002, 793.
36. 36 Inman, B.A., Sebo, T.J., Frigola, X., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer, 109, 2007, 1499.
37. 37 Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 387, 2016, 1909.
38. 38 Plimack, E.R., Bellmunt, J., Gupta, S., et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol, 33(suppl.), 2015, 4502.
39. 39 Rosenberg, S.A., Yang, J.C., Sherry, R.M., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res, 17, 2011, 4550.
40. 40 Sherif, A., Hasan, M.N., Marits, P., et al. Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. Eur Urol, 58, 2010, 105.
41. 41 Robbins, P.F., Morgan, R.A., Feldman, S.A., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol, 29, 2011, 917.
42. 42 Fishman, M.N., Hadjenberg, J., Kuzel, T., et al. Phase I/II clinical trial of ALT-801, a T-cell receptor/IL-2 fusion protein, plus gemcitabine and cisplatin in urothelial cancer. J Clin Oncol, 31(suppl.), 2013, 271.
43. 43 Gomes-Giacoia, E., Miyake, M., Goodison, S., et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One, 9, 2014, e96705.
44. 44 Falke, J., Lammers, R.J., Arentsen, H.C., et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol, 189, 2013, 2077.